139 related articles for article (PubMed ID: 37599513)
1. First case report of tumor lysis syndrome after third line systemic therapy with gemcitabine and pazopanib in a patient with lower extremity soft tissue sarcoma.
Benitez-Escobar EN; Galindes-Casanova DA; Melo-Burbano LÁ; Bonilla-Bonilla DM; Osorio-Toro LM; Daza-Arana JE; Escobar-Dávila SL; Rivas-Tafurt GP
Chin Clin Oncol; 2023 Aug; 12(4):45. PubMed ID: 37599513
[TBL] [Abstract][Full Text] [Related]
2. Pazopanib-related tumor lysis syndrome in metastatic clear cell renal cell carcinoma: a case report.
van Kalleveen MW; Walraven M; Hendriks MP
Invest New Drugs; 2018 Jun; 36(3):513-516. PubMed ID: 29464464
[TBL] [Abstract][Full Text] [Related]
3. A Phase Ib/II Study of Gemcitabine and Docetaxel in Combination With Pazopanib for the Neoadjuvant Treatment of Soft Tissue Sarcomas.
Munhoz RR; D'Angelo SP; Gounder MM; Keohan ML; Chi P; Carvajal RD; Singer S; Crago AM; Landa J; Healey JH; Qin LX; Hameed M; Ezeoke MO; Singh AS; Agulnik M; Chmielowski B; Luke JJ; Van Tine BA; Schwartz GK; Tap WD; Dickson MA
Oncologist; 2015 Nov; 20(11):1245-6. PubMed ID: 26449382
[TBL] [Abstract][Full Text] [Related]
4. Assessment of Predictive Biomarkers of the Response to Pazopanib Based on an Integrative Analysis of High-grade Soft-tissue Sarcomas: Analysis of a Tumor Sample from a Responder and Patients with Other Soft-tissue Sarcomas.
Suehara Y; Kohsaka S; Yamaguchi S; Hayashi T; Kurihara T; Sano K; Sasa K; Akaike K; Ueno T; Kojima S; Ikegami M; Mizuno S; Okubo T; Kim Y; Kaneko K; Saito T; Kato S; Mano H
Clin Orthop Relat Res; 2020 Nov; 478(11):2461-2476. PubMed ID: 32567826
[TBL] [Abstract][Full Text] [Related]
5. [Gemcitabine-induced tumor lysis syndrome caused by recurrent breast cancer in a patient without hemodialysis].
Kawaguchi Ushio A; Hattori M; Kohno N; Kaise H; Iwata H
Gan To Kagaku Ryoho; 2013 Nov; 40(11):1529-32. PubMed ID: 24231708
[TBL] [Abstract][Full Text] [Related]
6. Tumor lysis syndrome after treatment with gemcitabine for metastatic transitional cell carcinoma.
Lin CJ; Lim KH; Cheng YC; Chen HH; Wu CJ
Med Oncol; 2007; 24(4):455-7. PubMed ID: 17917099
[TBL] [Abstract][Full Text] [Related]
7. Recurrent chemotherapy-induced tumor lysis syndrome (TLS) with renal failure in a patient with chronic lymphocytic leukemia - successful treatment and prevention of TLS with low-dose rasburicase.
Hummel M; Buchheidt D; Reiter S; Bergmann J; Adam K; Hehlmann R
Eur J Haematol; 2005 Dec; 75(6):518-21. PubMed ID: 16313266
[TBL] [Abstract][Full Text] [Related]
8. Acute tumor lysis syndrome in solid tumors--a case report and review of the literature.
Baeksgaard L; Sørensen JB
Cancer Chemother Pharmacol; 2003 Mar; 51(3):187-92. PubMed ID: 12655435
[TBL] [Abstract][Full Text] [Related]
9. How we use pazopanib in treating soft-tissue sarcoma: experience at our multidisciplinary sarcoma centers.
Van Tine BA; Trent JC
Curr Med Res Opin; 2019 Apr; 35(4):623-629. PubMed ID: 30652922
[TBL] [Abstract][Full Text] [Related]
10. Effectiveness of Single-dose Rasburicase in Patients With Lymphoid Malignancies at a High Risk for Tumor Lysis Syndrome.
Jeon YW; Kwak DH; Park SS; Yoon JH; Lee SE; Eom KS; Kim YJ; Kim HJ; Lee S; Min CK; Lee JW; Min WS; Cho SG
Clin Lymphoma Myeloma Leuk; 2017 Sep; 17(9):595-603. PubMed ID: 28711571
[TBL] [Abstract][Full Text] [Related]
11. Anthracycline, Gemcitabine, and Pazopanib in Epithelioid Sarcoma: A Multi-institutional Case Series.
Frezza AM; Jones RL; Lo Vullo S; Asano N; Lucibello F; Ben-Ami E; Ratan R; Teterycz P; Boye K; Brahmi M; Palmerini E; Fedenko A; Vincenzi B; Brunello A; Desar IME; Benjamin RS; Blay JY; Broto JM; Casali PG; Gelderblom H; Grignani G; Gronchi A; Hall KS; Mir O; Rutkowski P; Wagner AJ; Anurova O; Collini P; Dei Tos AP; Flucke U; Hornick JL; Lobmaier I; Philippe T; Picci P; Ranchere D; Renne SL; Sbaraglia M; Thway K; Wagrodzki M; Wang WL; Yoshida A; Mariani L; Kawai A; Stacchiotti S
JAMA Oncol; 2018 Sep; 4(9):e180219. PubMed ID: 29800950
[TBL] [Abstract][Full Text] [Related]
12. A review of tumour lysis syndrome with targeted therapies and the role of rasburicase.
Bose P; Qubaiah O
J Clin Pharm Ther; 2011 Jun; 36(3):299-326. PubMed ID: 21501203
[TBL] [Abstract][Full Text] [Related]
13. Gemcitabine and docetaxel versus doxorubicin as first-line treatment in previously untreated advanced unresectable or metastatic soft-tissue sarcomas (GeDDiS): a randomised controlled phase 3 trial.
Seddon B; Strauss SJ; Whelan J; Leahy M; Woll PJ; Cowie F; Rothermundt C; Wood Z; Benson C; Ali N; Marples M; Veal GJ; Jamieson D; Küver K; Tirabosco R; Forsyth S; Nash S; Dehbi HM; Beare S
Lancet Oncol; 2017 Oct; 18(10):1397-1410. PubMed ID: 28882536
[TBL] [Abstract][Full Text] [Related]
14. Posterior reversible encephalopathy syndrome (PRES) induced by pazopanib, a multi-targeting tyrosine kinase inhibitor, in a patient with soft-tissue sarcoma: case report and review of the literature.
Deguchi S; Mitsuya K; Nakasu Y; Hayashi N; Katagiri H; Murata H; Wasa J; Takahashi M; Endo M
Invest New Drugs; 2018 Apr; 36(2):346-349. PubMed ID: 29067537
[TBL] [Abstract][Full Text] [Related]
15. Tumor Lysis Syndrome due to Eribulin Administration for Metastatic Undifferentiated Pleomorphic Sarcoma of the Buttock.
Tsuchie H; Miyakoshi N; Nagasawa H; Shimada Y
Acta Med Okayama; 2021 Aug; 75(4):533-538. PubMed ID: 34511623
[TBL] [Abstract][Full Text] [Related]
16. Rasburicase for the management of tumor lysis syndrome in neonates.
McNutt DM; Holdsworth MT; Wong C; Hanrahan JD; Winter SS
Ann Pharmacother; 2006; 40(7-8):1445-50. PubMed ID: 16868218
[TBL] [Abstract][Full Text] [Related]
17. Carfilzomib-associated tumor lysis syndrome.
Shely RN; Ratliff PD
Pharmacotherapy; 2014 May; 34(5):e34-7. PubMed ID: 24390940
[TBL] [Abstract][Full Text] [Related]
18. Systemic treatments in MDM2 positive intimal sarcoma: A multicentre experience with anthracycline, gemcitabine, and pazopanib within the World Sarcoma Network.
Frezza AM; Assi T; Lo Vullo S; Ben-Ami E; Dufresne A; Yonemori K; Noguchi E; Siontis B; Ferraro R; Teterycz P; Duffaud F; Ravi V; Vincenzi B; Gelderblom H; Pantaleo MA; Baldi GG; Desar I; Fedenko A; Maki RG; Jones RL; Benjamin RS; Blay JY; Kawai A; Gounder M; Gronchi A; Le Cesne A; Mir O; Czarnecka AM; Schuetze S; Wagner AJ; Adam J; Barisella M; Sbaraglia M; Hornick JL; Meurgey A; Mariani L; Casali PG; Thornton K; Stacchiotti S
Cancer; 2020 Jan; 126(1):98-104. PubMed ID: 31536651
[TBL] [Abstract][Full Text] [Related]
19. Phase II trial of gemcitabine as first line chemotherapy in patients with metastatic or unresectable soft tissue sarcoma.
Von Burton G; Rankin C; Zalupski MM; Mills GM; Borden EC; Karen A
Am J Clin Oncol; 2006 Feb; 29(1):59-61. PubMed ID: 16462504
[TBL] [Abstract][Full Text] [Related]
20. Tumour lysis syndrome and acute kidney injury in high-risk haematology patients in the rasburicase era. A prospective multicentre study from the Groupe de Recherche en Réanimation Respiratoire et Onco-Hématologique.
Darmon M; Vincent F; Camous L; Canet E; Bonmati C; Braun T; Caillot D; Cornillon J; Dimicoli S; Etienne A; Galicier L; Garnier A; Girault S; Hunault-Berger M; Marolleau JP; Moreau P; Raffoux E; Recher C; Thiebaud A; Thieblemont C; Azoulay E;
Br J Haematol; 2013 Aug; 162(4):489-97. PubMed ID: 23772757
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]